Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07082439 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 114 words Secondary endpoints: details revised at 4 of 7 entries · Collaborators: details revised at 1 of 1 entry Show 2 more changesShow less
    • Secondary endpoints: details revised at 4 of 7 entries
    • Collaborators: details revised at 1 of 1 entry
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 2025 to Sep 10, 2025 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Sep 2025 to Sep 10, 2025
    • Site details revised
  3. Start date: Jul 2025 to Sep 2025 Primary completion date: Jul 2027 to Sep 2027 · Completion date: Jul 2029 to Sep 2029v2 Show 2 more changesShow less
    • Primary completion date: Jul 2027 to Sep 2027
    • Completion date: Jul 2029 to Sep 2029
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the safety and effectiveness of the combination of pembrolizumab and odetiglucan in patients with metastatic colorectal cancer that is predominantly in the liver.
Trial Details
NCT Number NCT07082439
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Merck Sharp & Dohme LLC
Conditions Colorectal Adenocarcinoma Metastatic in the Liver
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov